{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113883.3.3616.200.110.102.1014",
  "meta": {
    "versionId": "5",
    "lastUpdated": "2022-07-13T01:02:20.000-04:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.1014",
  "version": "20220713",
  "name": "Casirivimab / Imdevimab Administration",
  "status": "active",
  "date": "2022-07-13T01:02:20-04:00",
  "publisher": "Clinical Architecture",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "concept": [
          {
            "code": "M0240",
            "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses"
          },
          {
            "code": "M0241",
            "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary\u0027s home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses"
          },
          {
            "code": "M0243",
            "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring"
          },
          {
            "code": "M0244",
            "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary\u0027s home that has been made provider-based to the hospital during the covid-19 public health emergency"
          },
          {
            "code": "Q0240",
            "display": "Injection, casirivimab and imdevimab, 600 mg"
          },
          {
            "code": "Q0243",
            "display": "Injection, casirivimab and imdevimab, 2400 mg"
          },
          {
            "code": "Q0244",
            "display": "Injection, casirivimab and imdevimab, 1200 mg"
          }
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:8c4fffd4-6875-417c-89cd-b73e3f4f2c01",
    "timestamp": "2022-09-28T05:22:47-04:00",
    "total": 7,
    "offset": 0,
    "parameter": [
      {
        "name": "count",
        "valueInteger": 1000
      },
      {
        "name": "offset",
        "valueInteger": 0
      }
    ],
    "contains": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "M0240",
        "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "M0241",
        "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary\u0027s home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "M0243",
        "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "M0244",
        "display": "Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary\u0027s home that has been made provider-based to the hospital during the covid-19 public health emergency"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "Q0240",
        "display": "Injection, casirivimab and imdevimab, 600 mg"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "Q0243",
        "display": "Injection, casirivimab and imdevimab, 2400 mg"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "Q0244",
        "display": "Injection, casirivimab and imdevimab, 1200 mg"
      }
    ]
  }
}